Anchor Capital Advisors LLC trimmed its position in shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) by 47.3% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,918 shares of the company’s stock after selling 9,815 shares during the period. Anchor Capital Advisors LLC’s holdings in Taro Pharmaceutical Industries were worth $1,230,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in TARO. Wells Fargo & Company MN lifted its stake in Taro Pharmaceutical Industries by 11.2% during the second quarter. Wells Fargo & Company MN now owns 1,685 shares of the company’s stock worth $189,000 after purchasing an additional 170 shares in the last quarter. Bessemer Group Inc. raised its stake in shares of Taro Pharmaceutical Industries by 138.6% in the second quarter. Bessemer Group Inc. now owns 2,083 shares of the company’s stock valued at $234,000 after acquiring an additional 1,210 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Taro Pharmaceutical Industries in the second quarter valued at $234,000. Bank of Montreal Can raised its stake in shares of Taro Pharmaceutical Industries by 7.5% in the second quarter. Bank of Montreal Can now owns 2,128 shares of the company’s stock valued at $238,000 after acquiring an additional 149 shares in the last quarter. Finally, Highstreet Asset Management Inc. acquired a new stake in shares of Taro Pharmaceutical Industries in the second quarter valued at $244,000. Institutional investors own 13.84% of the company’s stock.

Several equities analysts have issued reports on the company. BidaskClub lowered Taro Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Thursday, October 12th. TheStreet lowered Taro Pharmaceutical Industries from a “b-” rating to a “c+” rating in a report on Wednesday, August 9th.

Shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) traded down $3.82 during mid-day trading on Wednesday, hitting $113.28. The company’s stock had a trading volume of 250,900 shares, compared to its average volume of 95,754. The stock has a market capitalization of $4,744.07, a price-to-earnings ratio of 14.42 and a beta of 0.65. Taro Pharmaceutical Industries Ltd. has a 12 month low of $94.00 and a 12 month high of $128.46.

TRADEMARK VIOLATION NOTICE: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/11/15/anchor-capital-advisors-llc-decreases-holdings-in-taro-pharmaceutical-industries-ltd-taro.html.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Want to see what other hedge funds are holding TARO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taro Pharmaceutical Industries Ltd. (NYSE:TARO).

Institutional Ownership by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)

Receive News & Stock Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.